Literature DB >> 32474443

Kinetic Analysis of the Early Signaling Steps of the Human Chemokine Receptor CXCR4.

Cristina Perpiñá-Viciano1, Ali Işbilir1, Aurélien Zarca1, Birgit Caspar1, Laura E Kilpatrick1, Stephen J Hill1, Martine J Smit1, Martin J Lohse1, Carsten Hoffmann2.   

Abstract

G protein-coupled receptors (GPCRs) are biologic switches that transduce extracellular stimuli into intracellular responses in the cell. Temporally resolving GPCR transduction pathways is key to understanding how cell signaling occurs. Here, we investigate the kinetics and dynamics of the activation and early signaling steps of the CXC chemokine receptor (CXCR) 4 in response to its natural ligands CXC chemokine ligand (CXCL) 12 and macrophage migration inhibitory factor (MIF), using Förster resonance energy transfer-based approaches. We show that CXCR4 presents a multifaceted response to CXCL12, with receptor activation (≈0.6 seconds) followed by a rearrangement in the receptor/G protein complex (≈1 seconds), a slower dimer rearrangement (≈1.7 seconds), and prolonged G protein activation (≈4 seconds). In comparison, MIF distinctly modulates every step of the transduction pathway, indicating distinct activation mechanisms and reflecting the different pharmacological properties of these two ligands. Our study also indicates that CXCR4 exhibits some degree of ligand-independent activity, a relevant feature for drug development. SIGNIFICANCE STATEMENT: The CXC chemokine ligand (CXCL) 12/CXC chemokine receptor (CXCR) 4 axis represents a well-established therapeutic target for cancer treatment. We demonstrate that CXCR4 exhibits a multifaceted response that involves dynamic receptor dimer rearrangements and that is kinetically embedded between receptor-G protein complex rearrangements and G protein activation. The alternative endogenous ligand macrophage migration inhibitory factor behaves opposite to CXCL12 in each assay studied and does not lead to G protein activation. This detailed understanding of the receptor activation may aid in the development of more specific drugs against this target.
Copyright © 2020 by The Author(s).

Entities:  

Year:  2020        PMID: 32474443     DOI: 10.1124/mol.119.118448

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  3 in total

Review 1.  CXCR4 as a novel target in immunology: moving away from typical antagonists.

Authors:  Birgit Caspar; Pietro Cocchiara; Armelle Melet; Kristof Van Emelen; Annegret Van der Aa; Graeme Milligan; Jean-Philippe Herbeuval
Journal:  Future Drug Discov       Date:  2022-07-19

2.  Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.

Authors:  Ali Işbilir; Jan Möller; Marta Arimont; Vladimir Bobkov; Cristina Perpiñá-Viciano; Carsten Hoffmann; Asuka Inoue; Raimond Heukers; Chris de Graaf; Martine J Smit; Paolo Annibale; Martin J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-04       Impact factor: 11.205

3.  Probing the binding of interleukin-23 to individual receptor components and the IL-23 heteromeric receptor complex in living cells using NanoBRET.

Authors:  Charles S Lay; Angela Bridges; Joelle Goulding; Stephen J Briddon; Zoja Soloviev; Peter D Craggs; Stephen J Hill
Journal:  Cell Chem Biol       Date:  2021-05-25       Impact factor: 8.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.